GUILHERME GIANNINI ARTIOLI
Projetos de Pesquisa
Unidades Organizacionais
LIM/17 - Laboratório de Investigação em Reumatologia, Hospital das Clínicas, Faculdade de Medicina
7 resultados
Resultados de Busca
Agora exibindo 1 - 7 de 7
- The effect of carnosine or beta-alanine supplementation on markers of glycaemic control and insulin resistance in human and animal studies: a protocol for a systematic review and meta-analysis(2020) MATTHEWS, Joseph J.; DOLAN, Eimear; SWINTON, Paul A.; SANTOS, Livia; ARTIOLI, Guilherme G.; TURNER, Mark D.; ELLIOTT-SALE, Kirsty J.; SALE, CraigBackground Diabetes is a major public health issue and there is a need to develop low-cost, novel interventions to prevent or reduce disease progression. Growing evidence shows that supplementation with carnosine, or its rate-limiting precursor beta-alanine, can ameliorate aspects of the metabolic dysregulation that occurs in diabetes. There is, however, a need to develop a better understanding of the magnitude of effect and the factors associated with positive outcomes. The purpose of this systematic review and meta-analysis is to evaluate the effect of carnosine or beta-alanine supplementation on markers of glycaemic control and insulin resistance in humans and animals. Methods We will perform a systematic search for randomised and non-randomised controlled trials. Studies will be retrieved by searching electronic databases, clinical trial registers, author review, and cross-referencing. Primary outcomes include changes in (i) fasting glucose, (ii) glycated haemoglobin, and (iii) 2-h glucose following a glucose tolerance test. A set of additional outcomes includes other markers of glycaemic control and insulin resistance. Risk of bias (RoB) will be assessed using the Cochrane RoB 2.0 tool (human studies) and the Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE) RoB tool (animal studies). Confidence in the cumulative evidence will be assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. All meta-analyses will be conducted within a Bayesian framework, providing a flexible modelling approach to account for uncertainty in model parameters and underlying structures within the data. Discussion By including all available human and animal data, we will provide the most comprehensive overview on the topic to date. The results will have implications for those working in prediabetes, diabetes, and metabolic health in general and may lead to the development of new treatment approaches. Dissemination Study results will be presented at a professional conference and published in a peer-reviewed journal. Systematic review registration
bookPart 1 Citação(ões) na Scopus Biochemistry of buffering capacity and ingestion of buffers in exercise and athletic performance(2020) SAUNDERS, B.; ARTIOLI, G. G.; DOLAN, E.; JONES, R. L.; MATTHEWS, J.; SALE, C.- Insulin does not stimulate beta-alanine transport into human skeletal muscle(2020) GONCALVES, Livia de Souza; KRATZ, Caroline; SANTOS, Livia; CARVALHO, Victor Henrique; SALES, Lucas Peixoto; NEMEZIO, Kleiner; LONGOBARDI, Igor; RIANI, Luiz Augusto; LIMA, Marcelo Miranda de Oliveira; SAITO, Tiemi; FERNANDES, Alan Lins; RODRIGUES, Joice; JAMES, Ruth Margaret; SALE, Craig; GUALANO, Bruno; GELONEZE, Bruno; MEDEIROS, Marisa Helena Gennari de; ARTIOLI, Guilherme GianniniTo test whether high circulating insulin concentrations influence the transport of beta-alanine into skeletal muscle at either saturating or subsaturating beta-alanine concentrations, we conducted two experiments whereby beta-alanine and insulin concentrations were controlled. In experiment 1, 12 men received supraphysiological amounts of beta-alanine intravenously (0.11 g.kg(-1).min(-1) for 150 min), with or without insulin infusion. beta-Alanine and carnosine were measured in muscle before and 30 min after infusion. Blood samples were taken throughout the infusion protocol for plasma insulin and beta-alanine analyses. beta-Alanine content in 24-h urine was assessed. In experiment 2, six men ingested typical doses of beta-alanine (10 mg/kg) before insulin infusion or no infusion. beta-Alanine was assessed in muscle before and 120 min following ingestion. In experiment 1, no differences between conditions were shown for plasma beta-alanine, muscle beta-alanine, muscle carnosine and urinary beta-alanine concentrations (all P > 0.05). In experiment 2, no differences between conditions were shown for plasma beta-alanine or muscle beta-alanine concentrations (all P > 0.05). Hyperinsulinemia did not increase beta-alanine uptake by skeletal muscle cells, neither when substrate concentrations exceed the V-max of beta-alanine transporter TauT nor when it was below saturation. These results suggest that increasing insulin concentration is not necessary to maximize beta-alanine transport into muscle following beta-alanine intake.
- 24-Week beta-alanine ingestion does not affect muscle taurine or clinical blood parameters in healthy males(2020) SAUNDERS, Bryan; FRANCHI, Mariana; OLIVEIRA, Luana Farias de; SILVA, Vinicius da Eira; SILVA, Rafael Pires da; PAINELLI, Vitor de Salles; COSTA, Luiz Augusto Riani; SALE, Craig; HARRIS, Roger Charles; ROSCHEL, Hamilton; ARTIOLI, Guilherme Giannini; GUALANO, BrunoPurpose To investigate the effects of chronic beta-alanine (BA) supplementation on muscle taurine content, blood clinical markers and sensory side-effects. Methods Twenty-five healthy male participants (age 27 +/- 4 years, height 1.75 +/- 0.09 m, body mass 78.9 +/- 11.7 kg) were supplemented with 6.4 g day(-1) of sustained-release BA (N = 16; CarnoSyn (TM), NAI, USA) or placebo (PL; N = 9; maltodextrin) for 24 weeks. Resting muscle biopsies of the m. vastus lateralis were taken at 0, 12 and 24 weeks and analysed for taurine content (BA, N = 12; PL, N = 6) using high-performance liquid chromatography. Resting venous blood samples were taken every 4 weeks and analysed for markers of renal, hepatic and muscle function (BA, N = 15; PL, N = 8; aspartate transaminase; alanine aminotransferase; alkaline phosphatase; lactate dehydrogenase; albumin; globulin; creatinine; estimated glomerular filtration rate and creatine kinase). Results There was a significant main effect of group (p = 0.04) on muscle taurine, with overall lower values in PL, although there was no main effect of time or interaction effect (both p > 0.05) and no differences between specific timepoints (week 0, BA: 33.67 +/- 8.18 mmol kg(-1) dm, PL: 27.75 +/- 4.86 mmol kg(-1) dm; week 12, BA: 35.93 +/- 8.79 mmol kg(-1) dm, PL: 27.67 +/- 4.75 mmol kg(-1) dm; week 24, BA: 35.42 +/- 6.16 mmol kg(-1) dm, PL: 31.99 +/- 5.60 mmol kg(-1) dm). There was no effect of treatment, time or any interaction effects on any blood marker (all p > 0.05) and no self-reported side-effects in these participants throughout the study. Conclusions The current study showed that 24 weeks of BA supplementation at 6.4 g day(-1) did not significantly affect muscle taurine content, clinical markers of renal, hepatic and muscle function, nor did it result in chronic sensory side-effects, in healthy individuals. Since athletes are likely to engage in chronic supplementation, these data provide important evidence to suggest that supplementation with BA at these doses for up to 24 weeks is safe for healthy individuals.
- Risk of Increased Physical Inactivity During COVID-19 Outbreak in Older People: A Call for Actions(2020) ROSCHEL, Hamilton; ARTIOLI, Guilherme G.; GUALANO, Bruno
- Infographic. A systematic review and meta-analysis of the effect of beta-alanine supplementation on exercise capacity and performance(2020) SAUNDERS, Bryan; VIRGILE, Adam; ELLIOTT-SALE, Kirsty Jayne; ARTIOLI, Guilherme Giannini; SWINTON, Paul A.; DOLAN, Eimear; ROSCHEL, Hamilton; SALE, Craig; GUALANO, Bruno
- Magnetic Resonance Spectroscopy as a Non-invasive Method to Quantify Muscle Carnosine in Humans: a Comprehensive Validity Assessment(2020) SILVA, Vinicius da Eira; PAINELLI, Vitor de Salles; SHINJO, Samuel Katsuyuki; PEREIRA, Wagner Ribeiro; CILLI, Eduardo Maffud; SALE, Craig; GUALANO, Bruno; OTADUY, Maria Concepcion; ARTIOLI, Guilherme GianniniCarnosine is a dipeptide abundantly found in human skeletal muscle, cardiac muscle and neuronal cells having numerous properties that confers performance enhancing effects, as well as a wide-range of potential therapeutic applications. A reliable and valid method for tissue carnosine quantification is crucial for advancing the knowledge on biological processes involved with carnosine metabolism. In this regard, proton magnetic resonance spectroscopy (1H-MRS) has been used as a non-invasive alternative to quantify carnosine in human skeletal muscle. However, carnosine quantification by 1H-MRS has some potential limitations that warrant a thorough experimental examination of its validity. The present investigation examined the reliability, accuracy and sensitivity for the determination of muscle carnosine in humans using in vitro and in vivo experiments and comparing it to reference method for carnosine quantification (high-performance liquid chromatography - HPLC). We used in vitro 1H-MRS to verify signal linearity and possible noise sources. Carnosine was determined in the m. gastrocnemius by 1H-MRS and HPLC to compare signal quality and convergent validity. 1H-MRS showed adequate discriminant validity, but limited reliability and poor agreement with a reference method. Low signal amplitude, low signal-to-noise ratio, and voxel repositioning are major sources of error.